|Alfa Laval AB -- USA Stock|| |
USD 22.47 0.00 0.00%
Mr. Ulf Wiinberg has served as Independent Member of the Board of Directors of Alfa Laval AB since April 23, 2013. He is Former Chief Executive Officer of H. Lundbeck AS. Formerly, he was also director of Wyeth Pharmaceuticals, EMEACanada BioPharma, and held a number of other senior positions in Wyeth. He currently serves as Chairman of Avillion LLP, Hansa Medical AN, Trialbee AB and Sigrid Therapeutics, as well as Board Member of UCB Pharma and Agenus Inc.
Age: 57 Director Since 2013
46 46 36 65 00 http://www.alfalaval.com
The company has return on total asset (ROA)
of 5.26 %
which means that it generated profit of $5.26 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 9.23 %
meaning that it generated $9.23 on every $100 dollars invested by stockholders.
The company has accumulated 1.64 B in total debt with debt to equity ratio (D/E) of 70.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Alfa Laval AB has Current Ratio of 1.2 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.
Alfa Laval AB offer heat transfer, separation, and fluid handling solutions and solutions for use in various industries worldwide. Alfa Laval AB (ALFVF) is traded on OTC Market in USA. It is located in Lund, and employs 17,192 people.